Combination of PI3K/mTOR inhibition demonstrates efficacy in human chordoma

Anticancer Research

Volumn 29, Issue 6, 2009, Pages 1867-1871

  Schwab, Joseph ^a   Antonescu, Cristina ^b   Boland, Patrick ^b   Healey, John ^b   Rosenberg, Andrew ^a   Nielsen, Petur ^a   Iafrate, John ^a   Delaney, Thomas ^a   Yoon, Sam ^a   Choy, Edwin ^a   Harmon, David ^a   Raskin, Kevin ^a   Yang, Cao ^a   Mankin, Henry ^a   Springfield, Dempsey ^a   Hornicek, Francis ^a   Duan, Zhenfeng ^a  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

^b MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

Chordoma; mTOR; PI 103; PI3K

Indexed keywords

2 (4 HYDROXYPHENYL) 4 MORPHOLINOPYRIDO[3',2':4,5]FURO[3,2 D]PYRIMIDINE; CISPLATIN; DOXORUBICIN; MAMMALIAN TARGET OF RAPAMYCIN; PHOSPHATIDYLINOSITOL 3 KINASE; PHOSPHOINOSITIDE DEPENDENT PROTEIN KINASE 1; PROTEIN KINASE B;

APOPTOSIS; ARTICLE; CANCER CELL; CANCER INHIBITION; CELL PROLIFERATION; CHORDOMA; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG CYTOTOXICITY; DRUG EFFICACY; DRUG POTENTIATION; ENZYME INHIBITION; HUMAN; HUMAN CELL; HUMAN TISSUE; IN VITRO STUDY; PRIORITY JOURNAL; UPREGULATION;

1-PHOSPHATIDYLINOSITOL 3-KINASE; ANTIBIOTICS, ANTINEOPLASTIC; ANTINEOPLASTIC AGENTS; APOPTOSIS; BLOTTING, WESTERN; CELL PROLIFERATION; CHORDOMA; CISPLATIN; DOXORUBICIN; FURANS; HUMANS; PROTEIN KINASE INHIBITORS; PROTEIN KINASES; PROTO-ONCOGENE PROTEINS C-AKT; PYRIDINES; PYRIMIDINES; TUMOR CELLS, CULTURED;

EID: 67650928195     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (18)

1. Park LD, Liebsch N, Hornicek F, Goldberg S, Mankin H, Rosenberg A, Rosenthal D and Suit H: Sacral chordomas: impact of high-dose proton/photon-beam radiation therapy combined with or without surgery for primary versus recurrent tumor. Int. J Radiation Oncology Biol Phy 65(5): 1514-1521, 2006. (Pubitemid 44425209)
2. Fuchs B, Dickey ID, Yaszemski MJ, Inwards CY and Sim FH: Operative management of sacral chordoma. J Bone Joint Surg Am 87(10): 2211-2216, 2005.
3. Samson IR, Springfield DS, Suit HD and Mankin HJ: Operative treatment of sacrococcygeal chordoma. A review of twenty-one cases. J Bone Joint Surg Am 75(10): 1476-1484, 1993. (Pubitemid 23358235)
4. Higinbotham NL, Phillips RF, Farr HW and Hustu HO: Chordoma. Thirty-five-year study at Memorial Hospital. Cancer 20(11): 1841-1850, 1967.
5. Bergh P, Kindblom LG, Gunterberg B, Remotti F, Ryd W and Meis-Kindblom JM: Prognostic factors in chordoma of the sacrum and mobile spine: a study of 39 patients. Cancer 88(9): 2122-2134, 2000. (Pubitemid 30233215)
6. Casali PG, Messina A and Stacchiotti S: Imatinib mesylate in chordoma. Cancer 101(9): 2086-2097, 2004.
7. Helman LJ and Meltzer P: Mechanisms of sarcoma development. Nat Rev Cancer 3(9): 685-694, 2003.
8. Hill MM and Hemmings BA: Inhibition of protein kinase B/Akt. implications for cancer therapy. Pharmacol Ther 93(2-3): 243-251, 2002.
9. Wan X and Helman LJ: The biology behind mTOR inhibition in sarcoma. Oncologist 12(8): 1007-1018, 2007.
10. Krause DS and Van Etten RA: Tyrosine kinases as targets for cancer therapy. N Engl J Med 353(2): 172-187, 2005. (Pubitemid 41058349)
11. Fabian MA, Biggs WH 3rd and Treiber DK: A small molecule-kinase interaction map for clinical kinase inhibitors. Nat Biotechnol 23(3): 329-336, 2005.
12. Fan QW, Knight ZA and Goldenberg DD: A dual PI3 kinase/mTOR inhibitor reveals emergent efficacy in glioma. Cancer Cell 9(5): 341-349, 2006. (Pubitemid 43668732)
13. Scheil S, Bruderlein S and Liehr T: Genome-wide analysis of sixteen chordomas by comparative genomic hybridization and cytogenetics of the first human chordoma cell line, U-CH1. Genes Chromosomes Cancer 32(3): 203-211, 2001. (Pubitemid 32953974)
14. Duan Z, Lamendola DE, Yusuf RZ, Penson RT, Preffer FI and Seiden MV: Overexpression of human phosphoglycerate kinase 1 (PGK1) induces a multidrug resistance phenotype. Anticancer Res 22(4): 1933-1941, 2002. (Pubitemid 34857007)
15. Erdal H, Berndtsson M, Castro J, Brunk U, Shoshan MC and Linder S: Induction of lysosomal membrane permeabilization by compounds that activate p53-independent apoptosis. Proc Natl Acad Sci USA 102(1): 192-197, 2005. (Pubitemid 40094451)
16. Byfield MP, Murray JT and Backer JM: hVps34 is a nutrient-regulated lipid kinase required for activation of p70 S6 kinase. J Biol Chem 280(38): 33076-33082, 2005. (Pubitemid 41368357)
17. Nobukuni T, Joaquin M and Roccio M: Amino acids mediate mTOR/raptor signaling through activation of class 3 phosphatidylinositol 3OH-kinase. Proc Natl Acad Sci USA 102(40): 14238-14243, 2005. (Pubitemid 41429682)
18. Hay N: The Akt-mTOR tango and its relevance to cancer. Cancer Cell 8(3): 179-183, 2005. (Pubitemid 41317589)